Drug Discovery, Pharmaceuticals & Cannabis Testing
Expanding possibilities for diverse preclinical models
AMSBIO has broadened its array of products and services dedicated to supporting scientists in effectively diversifying their preclinical models, addressing the gender discrepancy gap prevalent in various research areas.
Historically, clinical trials predominantly involved men of European descent until 1993, resulting in limited data on treatment safety and effi cacy for women and diverse populations. While attitudes in clinical trials are evolving, inclusivity in preclinical research often remains overlooked, creating crucial knowledge gaps regarding the impact of drugs and treatments on different populations even before advancing to human trials.
In a recent blog commemorating International Women’s Day, AMSBIO discusses the potential use of an envisioned intestinal organoid biobank to address accessibility challenges. The blog also highlights the gender reporting issues in COVID-19 vaccine development, where women experienced a disproportionate number of side effects, underreported due to aggregated data.
As a global provider of human and animal biospecimens, AMSBIO contributes to increasing diversity in research. The company’s extensive biorepository houses various tissues from reliable sources, encompassing a comprehensive selection of healthy tissues and a variety of disease states from diverse genders and ethnicities. For specifi c research requirements, AMSBIO offers a custom tissue procurement service to provide samples tailored to the complexities of donor demographics.
Additionally, through a powerful synergy of novel organoids and proprietary lab-on-a-chip technology from partner ScreenIn3D (S3D), AMSBIO is uniquely positioned to assist preclinical researchers in cost-effectively developing high-throughput, data-rich assays.
Alex Sim, CEO of AMSBIO, emphasised: “A signifi cant impetus for future clinical trials emerged from the US Federal Drug Administration in 2023. The new FDA 2.0 legislation introduces additional stratifi cation in research by mandating more demographic requirements, including gender and race, for clinical trials and research programs. Both AMSBIO and ScreenIn3D can facilitate your research to translate this for societal benefi t and the positioning of combination therapies.”
Read the informative new blog ‘Diversifying Preclinical Research’:
ilmt.co/PL/vzQx More information online:
ilmt.co/PL/4m81
Distillation technology benefi tting clients worldwide
For decades, Pope has been dedicated to serving customers across diverse industries, enhancing existing products, and innovating new ones with proven distillation technology. The company provides equipment (now CE-certifi ed), process development, and toll processing services. Tailored strategies and equipment types are used to meet the unique requirements of different applications, ensuring optimal product quality, yield, and profi tability.
Wiped fi lm stills, also known as Short Path Stills, Molecular Stills, and Thin Film Evaporators, these are the best choice for materials high in heat sensitivity, BP, MW, and/or viscosity. These provide minimised thermal degradation via quick heat exposure time at high vacuum. Examples include pharmaceuticals, fl avours, edible oils, biomaterials, cannabinoids, polymers, lubricants, electronic materials, specialty chemicals, many more.
Wiped fi lm evaporators, also known as WFE’s, these have similarities to Molecular Stills, including rotating internal wipers, short residence time and gentle evaporation. However, they have external rather than internal condensers of high surface area and are best suited for driving off large percentages of solvents and concentrating dilute products.
Hybrid wiped fi lm evaporator-fractionators combine the advantages of gentle WFE evaporation and multiple theoretical plate packed columns to separate heat sensitive components close in BP. These systems have solved and commercialised some of the most diffi cult distillation operations. Pope is the world leader in this technology. Examples include Omega-3 concentration, natural fl avour customisation, biomaterials, many more.
Fractional column still systems specialise in stainless steel batch and continuous mode distillation systems from 1” to 18” diameters for pilot and production plants, Pope can address your multipurpose or specifi c application requirements.
More information online:
ilmt.co/PL/Ov2j 62307pr@reply-direct.com
62231pr@reply-direct.com
Advanced handheld Raman analyser for pharmaceutical applications
In a recent announcement, Thermo Fisher Scientifi c introduced the cutting-edge TruScan G3 Handheld Raman Analyzer, designed for swift raw material identifi cation in both small and large molecule pharmaceutical sectors.
The Thermo Scientifi cTM TruScanTM G3 Handheld Raman Analyzer represents a signifi cant leap forward in raw material identifi cation for the pharmaceutical and biotechnology industries. This portable, user-friendly device empowers operators with minimal training to conduct rapid identity testing on incoming starting materials, validate in-process substances, and distinguish fi nished drug products, ensuring process quality and audit readiness.
Building upon the success of the industry-leading TruScan RM Handheld Raman Analyzer, the TruScan G3 enables near real-time, non-destructive identifi cation of a wide array of chemical compounds, even through commonly used sealed packaging, eliminating the need for time-consuming laboratory testing. Packed with new features, including a built-in touchscreen display, enhanced sensor performance, updated compound libraries, an innovative immersion probe for in situ testing of solids and liquids, and improved connectivity and data compliance, the TruScan G3 stands out as Thermo Fisher’s most intuitive and accessible handheld analyser to date.
Xochitl Javier, Director of Product Management and Marketing at Thermo Fisher, expressed enthusiasm, stating: “As the pharmaceutical and biotechnology sectors increasingly embrace portable Raman testing as the go-to technique for material identifi cation, the all-new TruScan G3 Handheld Raman Analyzer builds on the legacy of its predecessor, allowing for quicker, easier, and more accurate incoming material verifi cation testing. Having this technology can support time and cost savings for our customers and the wider global pharmaceutical community.”
More information online:
ilmt.co/PL/2v7J 62203pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
